Skip to content
Learn More

Resources

iBio Joins the Alliance for Biosecurity

March 20, 2020

NEW YORK, March 20, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today announced that it has joined the Alliance for Biosecurity, a coalition of biopharmaceutical companies – along with laboratory and academic partners – that promotes a strong public-private partnership in order …

Read More

iBio Announces Development of Proprietary COVID-19 Vaccine Candidates

March 18, 2020

Several Provisional Patents Filed with USPTO NEW YORK, March 18, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today announced its progress towards developing vaccine candidates for preventing infection from the SARS-CoV-2 virus that causes the COVID-19 coronavirus disease. iBio created its SARS-CoV-2 …

Read More

iBio Announces Leadership Succession, Appoints Thomas F. Isett Co-Chairman & CEO

March 13, 2020

NEW YORK, March 12, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced the appointment of accomplished life sciences executive, Thomas F. Isett, as its Co-Chairman and Chief Executive Officer. Mr. Isett, a current member of iBio’s Board of Directors, succeeds Robert B. Kay, who has retired from the role …

Read More

iBio and CC-Pharming Initiate Joint Development of Coronavirus Vaccine

February 4, 2020

NEW YORK, Feb. 03, 2020 (GLOBE NEWSWIRE) — In response to investor and media inquiries regarding their initiatives to address the coronavirus outbreak, iBio, Inc. (NYSE AMERICAN:IBIO) and Beijing CC-Pharming Ltd., today announced their collaboration to develop and test a new 2019-nCoV vaccine to be manufactured using iBio’s FastPharming System™. The companies are expediting work as predictions about spread …

Read More

iBio Announces Collaboration with EdgePoint AI for Next Gen Quality in Biologics Manufacturing

December 24, 2019

NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc. (OTCQB:MATN), to deploy EdgePoint’s proprietary artificial intelligence (“AI”)/blockchain-driven vision system for pharmaceutical manufacturing, known as TrustPoint Fabric. Initial implementation will occur at iBio’s state-of-the-art production …

Read More
Top